Takeda Pharmaceutical (TAK) Notches Its Fourth 52-Week High in a Week
As seen on the 24/7 Wall St. homepage on October 26, 2026.
Takeda's ADRs just set a fresh 52-week high at $20.43, the fourth record in a week for the drugmaker.
Continue ReadingShow less
Takeda's American depositary receipts reached $20.43, the fourth 52-week high in a week. A streak like that points to sustained buying pressure.
The most recent leg of the climb has been particularly steep, with the stock pushing through $19 and then $20 in quick succession after trading in the mid-to-upper teens for much of the year.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
The latest record clears the prior 52-week high set on October 22 by just 0.34%. Investors will be watching whether the ADRs can hold above $20 on any pullback.
Takeda trades in the United States as depositary receipts, with the underlying shares also accessible through TKPHF. The combination of a multi-week momentum streak and back-to-back record closes makes this one of the more notable moves in large-cap international pharma right now.